Trial Profile

An Open-Label, Long Term Safety Study of SD-809 ER in Subjects With Chorea Associated With Huntington Disease

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 21 Oct 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Deutetrabenazine (Primary)
Indications Chorea; Huntington's disease
Focus Adverse reactions; Proof of concept; Registrational
Acronyms ARC-HD; ARC-HD Switch
Sponsors Auspex Pharmaceuticals

Most Recent Events

18 Oct 2022 According to a Teva Pharmaceuticals USA Media Release, this study was conducted in partnership with the Huntington Study Group (HSG).
18 Oct 2022 Results published in the Teva Pharmaceuticals USA Media Release.
15 Oct 2022 Results assessing the long-term safety and tolerability of deutetrabenazine for the treatment of Huntington disease, published in the CNS Drugs.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com